Intervention
Trastuzumab Rezetecan
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 10 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
10 shownReal-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerNCT07600164 · 2026-07-06
RECRUITINGThe Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral CrisisNCT07203729 · 2026-03-01
RECRUITINGTrastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard TherapiesNCT07309770 · 2025-12-18
RECRUITINGTrastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain MetastasesNCT07100600 · 2025-08-30
RECRUITINGTrastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNCT07766772 · 2026-09-30
NOT_YET_RECRUITINGFirst-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsNCT07699952 · 2026-09-09
NOT_YET_RECRUITINGTrastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene AbnormalitiesNCT07630077 · 2026-07-01
NOT_YET_RECRUITINGExploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid TumorNCT07631884 · 2026-06-15
NOT_YET_RECRUITINGTrastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHPNCT07589699 · 2026-05-31
NOT_YET_RECRUITINGTrastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCNCT07047755 · 2025-07-01
NOT_YET_RECRUITINGCommon conditions
Advanced Breast Cancer2Breast Cancer2HER2 + Breast Cancer2Advanced Malignant Solid Neoplasm1Advanced Solid Tumor Cancer1Antibody-drug Conjugates1Biliary Tract Neoplasms1Brain Metastases1Cervical Neoplasms1Colorectal Neoplasms1Early-stage Breast Cancer1EGFR Activating Mutation1Endometrial Neoplasms1Gastric Neoplasms1Head and Neck Neoplasms1HER21HER2 Expression1HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis1HER2-positive Advanced Breast Cancer1HER2-positive Breast Cancer1Locally Advanced Breast Cancer1Locally Advanced Malignant Solid Neoplasm1Lung Cancer (NSCLC)1Metastatic Malignant Solid Neoplasm1Neoplasms (Cancer / Tumors)1
Leading sponsors
Trial status mix
NOT_YET_RECRUITING6
RECRUITING4
Phase mix
PHASE28
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.